Franklin Resources
AKTX

Franklin Resources’s Akari Therapeutics AKTX Stock Holding History

Franklin Resources’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-88
Closed -$3.37M – 1583
2014
Q4 		$3.37M Hold
88
– – ﹤0.01% 1249
2014
Q3 		$4.13M Hold
88
– – ﹤0.01% 1212
2014
Q2 		$3.86M Buy
+88
New +$4.03M ﹤0.01% 1227

Other funds holding AKTX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Franklin Resources's AKTX Position: Q1 2015 in Review

Franklin Resources sold out of Akari Therapeutics (AKTX) in Q1 2015, closing a stake of 88 shares — an estimated $3.37M sold.

Franklin Resources first reported a position in AKTX in Q2 2014 and held it in 3 quarters. The position peaked at $4.13M in Q3 2014. 3 funds tracked by Wall St. Rank hold AKTX as of Q1 2015.

  • Franklin Resources reported no remaining Akari Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Franklin Resources sold 88 Akari Therapeutics shares in Q1 2015, an estimated $3.37M.
  • Franklin Resources first reported a position in Akari Therapeutics in Q2 2014 and held it in 3 quarters.
  • Franklin Resources's Akari Therapeutics position peaked at $4.13M in Q3 2014.
  • 3 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2015.

Based on Franklin Resources's 13F filing for Q1 2015, filed 14 May 2015.